Oyman, Abdilkerim Başak, Mustafa Özçelik, Melike Özyükseler, Deniz Tataroğlu Işık, Selver Yıldırım, Mahmut Emre
Published in
Asia-Pacific journal of clinical oncology
The aim of this study was to evaluate the efficacy of abiraterone in patients with castration-resistant metastatic prostate cancer. We retrospectively analyzed 51 patients with mCRPC treated with abiraterone acetate from January 2014 to August 2018. Clinicopathological information, treatment modalities, treatment responses, and survival times were ...
dyshlovoy, sergey a. pelageev, dmitry n. jakob, lea s. borisova, ksenia l. hauschild, jessica busenbender, tobias kaune, moritz khmelevskaya, ekaterina a. graefen, markus bokemeyer, carsten
...
Development of resistance to currently available standard therapies in advanced prostate cancer (PCa) emphasizes the need for novel therapeutic options. Here, we report the synthesis of new hybrid molecules consisting of 2-chloroethylthio and 1,4-naphthoquinone pharmacophores and describe their activity in PCa. In screening analyses, the introducti...
pandey, mitali cuddihy, grace gordon, jacob a. cox, michael e. wasan, kishor m.
There have been several studies that have linked elevated scavenger receptor class b type 1 (SR-B1) expression and activity to the development and progression of castration-resistant prostate cancer (CRPC). SR-B1 facilitates the influx of cholesterol to the cell from lipoproteins in systemic circulation. This influx of cholesterol may be important ...
ioannidou, evangelia moschetta, michele shah, sidrah parker, jack steven ozturk, mehmet akif pappas-gogos, george sheriff, matin rassy, elie boussios, stergios
Prostate cancer (PC) is the most common cancer in men and the second leading cause of cancer-related death worldwide. Many therapeutic advances over the last two decades have led to an improvement in the survival of patients with metastatic PC, yet the majority of these patients still succumb to their disease. Antiagiogenic therapies have shown sub...
Cole, Ryan Pascal, Laura E Wang, Zhou
Published in
American Journal of Clinical and Experimental Urology
This mini-review covers the classical model of androgen receptor (AR) nucleocytoplasmic trafficking and provides an overview of new data that updates the existing paradigm. The classical model of androgen receptor trafficking involves AR translocating to the nucleus in the presence of androgens and subsequently being exported back to the cytoplasm ...
Lo, U-Ging Chen, Yu-An Khamis, Zahraa I Kao, Wei-Hsiang Hsieh, Jer-Tsong Sang, Qing-Xiang Amy
Published in
American Journal of Clinical and Experimental Urology
First established by Dr. Leland W. K. Chung’s lab, the androgen-repressed prostate cancer cell (ARCaP) line is derived from the ascitic fluid of a prostate cancer (PCa) patient with widely metastatic disease. Based on its unique characteristic of growth suppression in the presence of androgen, ARCaP cell line has contributed to the research of PCa ...
Hamid, Agus Rizal A. H. Luna-Velez, Maria V. Dudek, Aleksandra M. Jansen, Cornelius F. J. Smit, Frank Aalders, Tilly W. Verhaegh, Gerald W. Schaafsma, Ewout Sedelaar, John P. M. Schalken, Jack A.
...
Published in
Frontiers in Oncology
Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen deprivation therapy (ADT). Several molecular changes, particularly in the AR signaling cascade, have been described that may explain ADT resistance. The variety of changes may also explain why the response to novel therapies varies between patients. Testin...
lopes, nair pacheco, mariana brütt soares-fernandes, diana correia, margareta p. camilo, vânia henrique, rui jerónimo, carmen
Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combinat...
benedetti, de
Prostate cancer (PCa) progression is characterized by the emergence of resistance to androgen deprivation therapy (ADT). AKT/PKB has been directly implicated in PCa progression, often due to the loss of PTEN and activation of PI3K> / PDK1> / AKT signaling. However, the regulatory network of AKT remains incompletely defined. Here, we describe th...
Gu, Renze Zhang, Qingchuan
Published in
Experimental and Therapeutic Medicine
Prostate cancer is the most prevalent tumor found in men worldwide. Despite the efficiency of primary endocrine prostate cancer therapies, more efficient drugs are needed to tackle the most advanced and resistant forms of this condition. The present study investigated the antitumor effects of low-dose bufalin combined with hydroxycamptothecin on ca...
